Immatics N.V Stock Price, News & Analysis
Company Description
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biopharmaceutical company active in the discovery and development of T cell‑redirecting cancer immunotherapies. According to company disclosures, Immatics focuses on precision targeting of PRAME, a target expressed in more than 50 cancers, and has built what it describes as the broadest PRAME franchise with multiple indications and modalities. The company combines the discovery of tumor‑associated targets with the development of T cell receptors (TCRs) to enable robust and specific T cell responses against cancer cells.
Immatics reports that its pipeline spans two main therapeutic approaches: Adoptive Cell Therapies (TCR T‑cell therapies) and TCR Bispecifics (TCER® molecules). Within this framework, the company is advancing several PRAME‑directed product candidates as well as a bispecific targeting MAGEA4/8. Immatics’ disclosures emphasize its role as a global leader in precision targeting of PRAME and its intention to make a meaningful impact on the lives of patients with cancer.
PRAME Cell Therapy Franchise
A central element of Immatics’ business is its PRAME cell therapy franchise. The company’s lead PRAME cell therapy is anzu‑cel (anzutresgene autoleucel, previously called IMA203), a TCR T‑cell therapy engineered to recognize an intracellular PRAME‑derived peptide presented by HLA‑A*02:01 on the cell surface and initiate a specific anti‑tumor response. Immatics states that anzu‑cel is its first PRAME therapy expected to enter the market in advanced melanoma, and that it is being evaluated in a registration‑enabling, randomized, controlled Phase 3 trial called SUPRAME in patients with unresectable or metastatic cutaneous melanoma who have received prior checkpoint inhibitor treatment.
In parallel with the Phase 3 program in cutaneous melanoma, anzu‑cel is being studied in a Phase 1b trial in patients with PRAME‑positive cancers, with a particular focus on metastatic uveal melanoma. Company updates describe a one‑time infusion approach, evaluation at a recommended Phase 2 dose range, and clinical data indicating anti‑tumor activity and durability in heavily pretreated melanoma populations, including cutaneous and uveal subgroups.
Second‑Generation PRAME Cell Therapy: IMA203CD8
Immatics is also developing IMA203CD8, described as a second‑generation PRAME‑directed TCR T‑cell therapy (GEN2). This product candidate is engineered to recognize a PRAME‑derived peptide presented by HLA‑A*02:01 and includes co‑transduction of CD8αβ alongside the PRAME TCR to add functional CD4+ T cells, which are designed to boost anti‑tumor activity. IMA203CD8 is being evaluated in an ongoing Phase 1a dose escalation trial in patients with advanced and/or metastatic solid tumors expressing PRAME, including melanoma, ovarian carcinoma and synovial sarcoma.
Data summarized in company press releases and a Form 6‑K filing highlight that IMA203CD8 has shown manageable tolerability and promising initial anti‑tumor activity across multiple PRAME‑expressing indications at a range of escalating doses. Immatics reports deep and durable objective responses, including complete and partial responses with substantial tumor reduction and responses lasting at least one year in some patients. The company has indicated a strategic goal to position IMA203CD8 in a tumor‑agnostic setting for advanced PRAME cancers beyond melanoma, starting with gynecologic cancers such as ovarian carcinoma.
TCR Bispecifics (TCER®) Pipeline
Beyond cell therapies, Immatics is advancing a next‑generation, half‑life extended TCR Bispecific platform, referred to as TCER®. These are antibody‑like, off‑the‑shelf biologics designed to redirect and activate T cells toward cancer cells expressing specific tumor targets. According to company descriptions, TCER molecules are engineered with two binding regions: a high‑affinity TCR domain that binds to a peptide–HLA complex on tumor cells, and a low‑affinity T cell recruiter domain directed against the CD3 complex to engage T cells. The format includes an Fc part for half‑life extension, stability and manufacturability, and is intended to support dosing schedules that are compatible with standard pharmaceutical distribution.
Within this platform, Immatics is developing IMA402, a PRAME‑directed TCR Bispecific, and IMA401, a MAGEA4/8‑directed TCR Bispecific. Both are being evaluated in Phase 1a clinical trials in heavily pretreated patients with a range of solid tumors. Company data show that IMA402 has achieved clinical proof‑of‑concept with favorable tolerability at a recommended Phase 2 dose range and deep, durable responses in indications such as melanoma and ovarian carcinoma. IMA401 has also demonstrated clinical activity and durable responses in patients with head and neck cancer, melanoma and squamous non‑small cell lung cancer at doses within its recommended range.
Scientific and Operational Approach
Immatics describes its core expertise as combining the discovery of “true targets” for cancer immunotherapies with the development of the “right” T cell receptors. This know‑how underpins its pipeline of adoptive cell therapies and TCR Bispecifics and supports collaborations with global pharmaceutical partners. The company has referenced the use of proprietary discovery platforms, including XPRESIDENT® and the bioinformatics and AI platform XCUBE™, in the context of a collaboration with Moderna, where Immatics generated regulatory support data for an mRNA product candidate.
On the operational side, Immatics has disclosed the establishment of in‑house, state‑of‑the‑art cell therapy manufacturing capabilities to support late‑stage clinical development and potential commercial supply of its PRAME cell therapy products. The company has also reported revenue from strategic collaboration agreements with third‑party pharmaceutical and biotechnology companies, consistent with its earlier description of earning revenue through such collaborations, and notes that it files annual reports under Form 20‑F as a foreign private issuer.
Geographic Footprint and Regulatory Status
Company press releases and SEC filings identify Immatics N.V. as a foreign private issuer with principal executive offices in Tübingen in the Federal Republic of Germany. The company also issues press releases from locations in Texas, such as Houston and Stafford, reflecting a transatlantic operational presence. Immatics’ ordinary shares trade on the NASDAQ under the symbol IMTX, and the company has referenced regulatory interactions in both the United States and Europe, including FDA designations and approvals from European regulatory authorities for clinical trial conduct.
Collaborations and Partnerships
Immatics has disclosed multiple collaboration agreements with large biopharmaceutical companies. These include collaborations with Moderna, Bristol Myers Squibb and Genmab, among others, as reflected in its interim financial reports and related SEC filings. Under a collaboration agreement with Moderna, Immatics received a milestone payment triggered by initiation of a Phase 1 clinical trial for a Moderna product candidate that used Immatics’ target discovery and data platforms. These collaborations contribute to the company’s revenue from strategic agreements and support the development of both its own pipeline and partner programs.
Business Model and Sector Context
Within the broader manufacturing sector classification of biological product (except diagnostic) manufacturing, Immatics operates as a clinical‑stage biopharmaceutical company focusing on T cell‑redirecting immunotherapies. Its business model, as described in company and Polygon data, centers on discovering cancer targets, engineering TCR‑based therapeutics, advancing these candidates through clinical development, and generating revenue through strategic collaboration agreements. The company emphasizes its commitment to patients with cancers that have limited effective treatment options, such as advanced cutaneous melanoma, metastatic uveal melanoma, ovarian carcinoma and other PRAME‑expressing solid tumors.
FAQs about Immatics N.V. (IMTX)
- What does Immatics N.V. do?
Immatics N.V. is a clinical‑stage biopharmaceutical company focused on the discovery and development of T cell‑redirecting cancer immunotherapies. It concentrates on precision targeting of PRAME and develops both TCR T‑cell therapies and TCR Bispecifics for patients with solid tumors. - What is PRAME and why is it important to Immatics?
PRAME is a target that Immatics reports is expressed in more than 50 cancers. The company has built a PRAME franchise with multiple product candidates and modalities, including cell therapies and bispecific antibodies, aiming to address a broad set of PRAME‑positive tumors. - What are Immatics’ main product candidates?
Key disclosed product candidates include anzu‑cel (anzutresgene autoleucel, formerly IMA203) PRAME cell therapy, IMA203CD8 second‑generation PRAME cell therapy, IMA402 PRAME TCR Bispecific, and IMA401 MAGEA4/8 TCR Bispecific. These are in various phases of clinical development in solid tumors. - How does Immatics generate revenue?
According to Polygon data and company filings, Immatics generates revenue primarily through strategic collaboration agreements with third‑party pharmaceutical and biotechnology companies. Recent interim reports describe revenue from collaboration agreements and milestone payments under these partnerships. - On which exchange is Immatics stock listed and under what symbol?
Immatics N.V. is listed on the NASDAQ stock market under the ticker symbol IMTX, as indicated in its press releases and SEC filings. - In which therapeutic areas is Immatics currently running clinical trials?
Company communications describe clinical trials in advanced and/or metastatic solid tumors expressing PRAME, including unresectable or metastatic cutaneous melanoma, metastatic uveal melanoma, ovarian carcinoma, synovial sarcoma and other PRAME‑positive cancers. Additional trials involve tumors expressing MAGEA4/8. - What is the SUPRAME trial?
SUPRAME is the name of Immatics’ randomized, controlled, multi‑center Phase 3 clinical trial evaluating anzu‑cel (IMA203) PRAME cell therapy versus investigator’s choice in patients with unresectable or metastatic cutaneous melanoma who have received prior checkpoint inhibitor therapy. - How does Immatics describe its TCR Bispecific (TCER®) technology?
Immatics describes its TCER molecules as half‑life extended, off‑the‑shelf biologics with a high‑affinity TCR domain targeting peptide–HLA complexes on tumor cells and a low‑affinity CD3‑directed recruiter domain to engage T cells. The format includes an Fc region for half‑life extension, stability and manufacturability. - Does Immatics have collaborations with other pharmaceutical companies?
Yes. Immatics’ filings and press releases reference collaborations with companies such as Moderna, Bristol Myers Squibb and Genmab, among others, which involve target discovery, data platforms and co‑development activities. - Is Immatics a commercial‑stage or clinical‑stage company?
Immatics consistently describes itself as a clinical‑stage biopharmaceutical company. Its programs are in various phases of clinical development, and it has discussed preparations for a potential transition to commercial stage as its lead PRAME cell therapy advances.